Linked Life Data

17665331

Source:http://linkedlifedata.com/resource/pubmed/id/17665331

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2007-7-31
pubmed:abstractText
The past decades have brought major breakthroughs in the identification of distinct genetic alterations (eg, mutations, chromosomal aberrations) in various human tumors, leading to the development and clinical use of novel target-specific antibodies and small molecules. Recently, variable modifications of chromatin elements have become the focus of cell biology research. Compounds that inhibit the key chromatin-modifying enzyme classes of histone deacetylase (HDAC) and DNA methyltransferase (DNMT) are currently being evaluated in various preclinical studies and clinical trials. The overexpression of both HDAC and DNMT has been demonstrated to be associated with the epigenetic inactivation of tumor suppressor genes, as well as cell cycle and apoptosis regulators. In addition, inhibitors of HDAC and DNMT possess direct cytotoxic properties, and can sensitize tumor cells to conventional radiotherapy and chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1369-7056
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
557-61
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
pubmed:affiliation
Department of Medicine 1, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.
pubmed:publicationType
Journal Article, Review